SubsidieMeestersA novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO
Developing a combination of meropenem and ANT3310 to combat drug-resistant Gram-negative infections, aiming for market approval by 2029 and projected sales over €10bn in 13 years.
Projectdetails
Introduction
Antimicrobial resistance (AMR) due to multidrug-resistant Gram-negative bacteria is an increasingly serious healthcare threat, exacerbated by major economic issues underlying the development of new antibacterial drugs.
Problem Statement
The effectiveness of β-lactam antibiotics, the most important class of antibacterial agents, is impaired by the production of β-lactamase enzymes by drug-resistant bacteria.
Solution Development
We are developing a combination of a well-known antibiotic (meropenem) and ANT3310, our proprietary, best-in-class serine-β-lactamase inhibitor, intended for the treatment of hospital-acquired infections caused by drug-resistant pathogens.
Efficacy
Our treatment has been pre-clinically proven to be efficacious against all three pathogens deemed a critical priority by the World Health Organization (WHO).
Clinical Trials and Market Strategy
We will conduct three clinical trials and subsequently out-license ANT3310 to a pharmaceutical partner.
Market Expectations
We expect market approval by 2029 and anticipate that ANT3310 will generate over €10bn in sales within 13 years.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 23.984.442 |
Tijdlijn
| Startdatum | 1-2-2023 |
| Einddatum | 30-4-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ANTABIOpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infectionsLeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations. | EIC Pathfinder | € 2.665.564 | 2022 | Details |
Bacteriocins from interbacterial warfare as antibiotic alternativeBACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health. | ERC ADG | € 2.500.000 | 2023 | Details |
Antibiotic Lead OptimizationThis project aims to optimize and evaluate a novel DnaN inhibitor, WAM-N17, to develop new antibiotics targeting multidrug-resistant bacteria through compound synthesis and in vivo studies. | ERC POC | € 150.000 | 2023 | Details |
PReclinical EVAluation and Investigation of Laterocidamide - A novel antibiotic from a new drug class to overcome polymyxin resistance.Project PREVAIL aims to validate the novel antibiotic Laterocidamide (LATERO) against polymyxin-resistant Gram-negative bacteria, addressing antibiotic resistance while exploring its commercial potential. | ERC POC | € 150.000 | 2024 | Details |
Targeted Nano-formulations for Treatment of MRSA: A multicomponent platform for nano-formulated treatment of resistant microbial infections
LeadToTreat aims to develop targeted nano-formulations for treating MRSA infections by co-delivering novel low-drugability compounds and synergistic antibiotic combinations.
Bacteriocins from interbacterial warfare as antibiotic alternative
BACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health.
Antibiotic Lead Optimization
This project aims to optimize and evaluate a novel DnaN inhibitor, WAM-N17, to develop new antibiotics targeting multidrug-resistant bacteria through compound synthesis and in vivo studies.
PReclinical EVAluation and Investigation of Laterocidamide - A novel antibiotic from a new drug class to overcome polymyxin resistance.
Project PREVAIL aims to validate the novel antibiotic Laterocidamide (LATERO) against polymyxin-resistant Gram-negative bacteria, addressing antibiotic resistance while exploring its commercial potential.